Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.
about
Targeting Staphylococcus aureus Toxins: A Potential form of Anti-Virulence TherapyThe Role of Staphylococcus aureus Virulence Factors in Skin Infection and Their Potential as Vaccine AntigensInvestigational drugs to treat methicillin-resistant Staphylococcus aureusStaphylococcus aureus α-toxin: nearly a century of intrigueCurrent concepts on the virulence mechanisms of meticillin-resistant Staphylococcus aureusSafety, Tolerability, and Pharmacokinetics of MEDI4893, an Investigational, Extended-Half-Life, Anti-Staphylococcus aureus Alpha-Toxin Human Monoclonal Antibody, in Healthy AdultsA novel anti-PcrV antibody providing enhanced protection against Pseudomonas aeruginosa in multiple animal infection models.The potential use of toxin antibodies as a strategy for controlling acute Staphylococcus aureus infections.Role of antibodies in protection elicited by active vaccination with genetically inactivated alpha hemolysin in a mouse model of staphylococcus aureus skin and soft tissue infections.The psmα locus regulates production of Staphylococcus aureus alpha-toxin during infectionHumanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycinDevelopment of a mimotope vaccine targeting the Staphylococcus aureus quorum sensing pathway.Passive immunization with anti-glucosaminidase monoclonal antibodies protects mice from implant-associated osteomyelitis by mediating opsonophagocytosis of Staphylococcus aureus megaclusters.Characterization of alpha-toxin hla gene variants, alpha-toxin expression levels, and levels of antibody to alpha-toxin in hemodialysis and postsurgical patients with Staphylococcus aureus bacteremia.Anti-alpha-toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model.Basis of virulence in a Panton-Valentine leukocidin-negative community-associated methicillin-resistant Staphylococcus aureus strain.Cyclodextrin derivatives as anti-infectives.Staphylococcus aureus alpha toxin suppresses effective innate and adaptive immune responses in a murine dermonecrosis model.Identification and validation of a linear protective neutralizing epitope in the β-pore domain of alpha toxin.Five birds, one stone: neutralization of α-hemolysin and 4 bi-component leukocidins of Staphylococcus aureus with a single human monoclonal antibody.Target-Agnostic Identification of Functional Monoclonal Antibodies Against Klebsiella pneumoniae Multimeric MrkA Fimbrial Subunit.Selection of Recombinant Human Antibodies.Antigen-specific single B cell sorting and expression-cloning from immunoglobulin humanized rats: a rapid and versatile method for the generation of high affinity and discriminative human monoclonal antibodies.MAE4, an eLtaS monoclonal antibody, blocks Staphylococcus aureus virulence.Crystallization and preliminary X-ray diffraction analysis of the complex between a human anti-alpha toxin antibody fragment and alpha toxin.Epicutaneous model of community-acquired Staphylococcus aureus skin infections.Effects of linezolid on suppressing in vivo production of staphylococcal toxins and improving survival outcomes in a rabbit model of methicillin-resistant Staphylococcus aureus necrotizing pneumonia.Targeting Alpha Toxin and ClfA with a Multimechanistic Monoclonal-Antibody-Based Approach for Prophylaxis of Serious Staphylococcus aureus DiseaseStaphylococcus aureus Alpha-Toxin Is Conserved among Diverse Hospital Respiratory Isolates Collected from a Global Surveillance Study and Is Neutralized by Monoclonal Antibody MEDI4893Critical Role of Alpha-Toxin and Protective Effects of Its Neutralization by a Human Antibody in Acute Bacterial Skin and Skin Structure Infections.Staphylococcal Enterotoxin B-specific monoclonal antibody 20B1 successfully treats diverse Staphylococcus aureus infections.Assessment of an anti-alpha-toxin monoclonal antibody for prevention and treatment of Staphylococcus aureus-induced pneumoniaHost-inherent variability influences the transcriptional response of Staphylococcus aureus during in vivo infection.Staphylococcal bicomponent pore-forming toxins: targets for prophylaxis and immunotherapy.The Innovative Medicines Initiative's New Drugs for Bad Bugs programme: European public-private partnerships for the development of new strategies to tackle antibiotic resistance.Multimechanistic Monoclonal Antibodies (MAbs) Targeting Staphylococcus aureus Alpha-Toxin and Clumping Factor A: Activity and Efficacy Comparisons of a MAb Combination and an Engineered Bispecific Antibody Approach.Adaptive Immunity Against Staphylococcus aureus.The complex biology and contribution of Staphylococcus aureus in atopic dermatitis, current and future therapies.Mechanisms of neutralization of a human anti-α-toxin antibody.α-Toxin Regulates Local Granulocyte Expansion from Hematopoietic Stem and Progenitor Cells in Staphylococcus aureus-Infected Wounds.
P2860
Q26752975-475EBD5B-43E1-461E-8452-B08417EBC1AFQ26768436-3436E3DE-CBB3-4738-843D-C18ECECDC07FQ26780246-3AE541BA-D0BC-423F-A1BE-E48EB4CE8DA4Q26823686-B5740B82-4C86-4755-9BD2-BA8242D8EF78Q27023330-4DA4A2AA-0810-4BF5-89C8-ED39A6665FCAQ28354370-98DCE275-D46E-4CE1-A903-977EB884E413Q30408273-CA7A8C99-D4E3-4526-AEFD-15D9D70775DEQ30415990-B5A87AFC-CE77-42A8-AA4E-D7BBA697ECB5Q33601802-55390C87-1EDA-457F-AE8A-3F7D27C630C3Q34058980-A4015DB8-C681-4824-B97E-38D70484F299Q34315661-35F4DEF5-E6FE-4506-9F03-FD24F3DEFBFAQ34472793-32645491-770E-4C73-AA27-798D6270DEFFQ34522708-FBE16FD9-D300-4012-9754-51E84B5BC24FQ34916584-633DEC6F-D37A-445F-9FF9-0C029406CFCCQ34922452-31DFFBD3-0D93-4575-B46B-08239B97D075Q34974780-53EB37E6-9377-421B-9942-2556F96537DEQ34980556-8043788E-F641-451A-9315-26FF76019DAEQ35009064-92A0A94C-8D28-410B-A296-6405B08FC483Q35031839-F6DE3C22-986E-4AA4-8A83-67736FBFF5D1Q35530119-9BD426EF-498D-4A18-A317-8E081B4D317AQ35894482-47315397-44D2-4825-A011-C5952EB2BF7CQ36033281-DD9A4311-4638-48FA-B893-AE9E6A9A02D0Q36248059-B4D42179-9964-4828-B559-CBD3613353E9Q36310242-13B436B0-F825-40AD-83F1-EB4BE670FD46Q36711073-52FADE6F-67A9-48E4-9AB6-3697A47A90D8Q36804704-CFA79C99-91FE-4803-B1C6-EE29C35A1040Q36882495-CF1832F2-1353-4219-9403-803B045DB2D0Q37075941-15C71247-480A-4EFC-AA2F-ABE831FF2CA1Q37203734-BBE61B06-67B4-4301-BFCA-3D4F670E9F8DQ37287845-11EBD745-3099-4881-82DD-6F5631048E5DQ37332203-10AC6BD6-3FA6-46F4-8668-2AC2ACD0A52AQ37544870-F8DF8FB7-550D-4876-993A-ECDA54B0F5A7Q37630382-08CE9007-B18E-402B-AD43-85B0A28798CBQ38193690-172D2478-9D32-43A2-98F9-D29A02745D8EQ38633668-ABD26BED-B4BE-4E9D-8C12-884CE8C88712Q38674449-A96DE017-C40A-4F20-A613-14AE1A110283Q38751767-B4E6B0A1-480A-49FC-969F-5D256210C94FQ38805996-3425C913-860C-46EA-9360-B6F6EF738E22Q38957590-8F8306BE-A0B8-4B15-A24B-4E7AF88AF483Q40124323-A5C9247B-A084-4494-B1C4-34AF70E4F46B
P2860
Identification of anti-alpha toxin monoclonal antibodies that reduce the severity of Staphylococcus aureus dermonecrosis and exhibit a correlation between affinity and potency.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Identification of anti-alpha t ...... between affinity and potency.
@ast
Identification of anti-alpha t ...... between affinity and potency.
@en
type
label
Identification of anti-alpha t ...... between affinity and potency.
@ast
Identification of anti-alpha t ...... between affinity and potency.
@en
prefLabel
Identification of anti-alpha t ...... between affinity and potency.
@ast
Identification of anti-alpha t ...... between affinity and potency.
@en
P2093
P2860
P356
P1476
Identification of anti-alpha t ...... between affinity and potency.
@en
P2093
B R Sellman
C K Stover
L Dettinger
P Chowdhury
R S MacGill
P2860
P304
P356
10.1128/CVI.05589-11
P577
2012-01-11T00:00:00Z